Hepatitis C drug costs beat alternative: Merck

May the best drug win. That's how Merck Chief Executive Ken Frazier views the rising competition for hepatitis C treatments.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.